{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:47:49Z","timestamp":1790758069070,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Bill & Melinda Gates Foundation, Seattle, WA","award":["OPP1130379"],"award-info":[{"award-number":["OPP1130379"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.smim.2018.10.004","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T19:50:36Z","timestamp":1540324236000},"page":"22-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Correlates of GLA family adjuvants\u2019 activities"],"prefix":"10.1016","volume":"39","author":[{"given":"Steven G.","family":"Reed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5901-3402","authenticated-orcid":false,"given":"Darrick","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3609-661X","authenticated-orcid":false,"given":"Corey","family":"Casper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8515-5516","authenticated-orcid":false,"given":"Malcolm S.","family":"Duthie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2018.10.004_bib0005","first-page":"2654","article-title":"Isolation of a nontoxic lipid a fraction containing tumor regression activity","volume":"41","author":"Takayama","year":"1981","journal-title":"Cancer Res."},{"issue":"October","key":"10.1016\/j.smim.2018.10.004_bib0010","first-page":"11808","article-title":"Purification and structural determination of nontoxic LipidA obtained from the lipopolysaccharide of salmonella Typhimurium","volume":"257","author":"Ribi","year":"1982","journal-title":"J Biol Chem."},{"key":"10.1016\/j.smim.2018.10.004_bib0015","first-page":"1","article-title":"Beneficial modification of the endotoxin molecule","volume":"3","author":"Ribi","year":"1984","journal-title":"J. Biol. Response Mod."},{"key":"10.1016\/j.smim.2018.10.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199701093360202","article-title":"A preliminary evaluation of a recombinant circumsporozoite protein vaccine against plasmodium falciparum malaria","author":"Stoute","year":"1997","journal-title":"Engl. J."},{"key":"10.1016\/j.smim.2018.10.004_bib0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/600120","article-title":"Randomized, double\u2010blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria\u2010naive adults: safety, efficacy, and immunologic associates of protection","volume":"200","author":"Kester","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2018.10.004_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006465","article-title":"Evaluation of RTS,S\/AS02A and RTS,S\/AS01B in adults in a high malaria transmission area","volume":"4","author":"Polhemus","year":"2009","journal-title":"PLoS One."},{"key":"10.1016\/j.smim.2018.10.004_bib0035","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.vaccine.2012.05.035","article-title":"Improved CD4+T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72\/AS01 as compared to the M72\/AS02 and Mtb72F\/AS02 tuberculosis candidate vaccine formulations: a randomized trial","volume":"31","author":"Leroux-Roels","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.10.004_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00943","article-title":"Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans","volume":"8","author":"Burny","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.smim.2018.10.004_bib0045","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1016\/j.vaccine.2014.03.040","article-title":"Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials","volume":"32","author":"Van Damme","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.10.004_bib0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/21645515.2016.1225635","article-title":"From discovery to licensure, the adjuvant system story","volume":"13","author":"Gar\u00e7on","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.smim.2018.10.004_bib0055","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.colsurfb.2013.09.006","article-title":"In vitro evaluation of TLR4 agonist activity: formulation effects","volume":"113","author":"Misquith","year":"2014","journal-title":"Colloids Surfaces B: Biointerfaces."},{"key":"10.1016\/j.smim.2018.10.004_bib0060","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","article-title":"Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells","volume":"193","author":"Didierlaurent","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2018.10.004_bib0065","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum Salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2018.10.004_bib0070","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1016\/j.vaccine.2007.06.049","article-title":"Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response","volume":"25","author":"Hansen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.10.004_bib0075","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.vaccine.2012.01.070","article-title":"Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens","volume":"30","author":"Watson","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.10.004_bib0080","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijpharm.2015.03.028","article-title":"Design and preclinical characterization of a novel vaccine adjuvant formulation consisting of a synthetic TLR4 agonist in a thermoreversible squalene emulsion","volume":"486","author":"Haensler","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.smim.2018.10.004_bib0085","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/jps.23868","article-title":"Modulating potency: physicochemical characteristics are a determining factor of TLR4-agonist nanosuspension activity","volume":"103","author":"Dowling","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.smim.2018.10.004_bib0090","doi-asserted-by":"crossref","first-page":"26307","DOI":"10.1074\/jbc.M401231200","article-title":"Aggregates are the biologically active units of endotoxin","volume":"279","author":"Mueller","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.smim.2018.10.004_bib0095","first-page":"814","article-title":"New generation adjuvants \u2013 from empiricism to rational design New generation adjuvants \u2013 from empiricism to rational design","volume":"33S","author":"Hagan","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.10.004_bib0100","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jconrel.2013.10.032","article-title":"Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles","volume":"173","author":"Li","year":"2014","journal-title":"J. Control. Release."},{"key":"10.1016\/j.smim.2018.10.004_bib0105","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1021\/nn404211j","article-title":"Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles","volume":"7","author":"Sun","year":"2013","journal-title":"ACS Nano."},{"key":"10.1016\/j.smim.2018.10.004_bib0110","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jps.24295","article-title":"Glassy-state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid a adjuvants","volume":"104","author":"Hassett","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.smim.2018.10.004_bib0115","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jconrel.2013.12.025","article-title":"Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization","volume":"177","author":"Orr","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.smim.2018.10.004_bib0120","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.2147\/IJN.S159839","article-title":"Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach","volume":"13","author":"Kramer","year":"2018","journal-title":"Int. J. Nanomedicine."},{"key":"10.1016\/j.smim.2018.10.004_bib0125","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1128\/JVI.00207-09","article-title":"Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge","volume":"83","author":"Perrone","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2018.10.004_bib0130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/nyas.12462","article-title":"Continuing challenges in influenza","volume":"1323","author":"Webster","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.smim.2018.10.004_bib0135","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/ncomms1769","article-title":"BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-\u03baB pathway","volume":"3","author":"Pone","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2018.10.004_bib0140","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/eji.201444543","article-title":"Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-\u03b3","volume":"45","author":"Desbien","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.smim.2018.10.004_bib0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002135","article-title":"Targeting TLRs expands the antibody repertoire in response to a malaria vaccine","volume":"3","author":"Wiley","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2018.10.004_bib0150","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1128\/JVI.03337-14","article-title":"Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce Rapid, sustained, and broadly protective responses","volume":"89","author":"Goff","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2018.10.004_bib0155","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1016\/j.vaccine.2013.08.064","article-title":"Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5\/Indonesia\/05\/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant","volume":"31","author":"Treanor","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.10.004_bib0160","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.coph.2018.03.014","article-title":"Adjuvant strategies to improve vaccination of the elderly population","volume":"41","author":"Weinberger","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.smim.2018.10.004_bib0165","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1073\/pnas.0712077106","article-title":"Defined tuberculosis vaccine, Mtb72F\/AS02A, evidence of protection in cynomolgus monkeys","volume":"106","author":"Reed","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.smim.2018.10.004_bib0170","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001094","article-title":"A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant mycobacterium tuberculosis","volume":"2","author":"Bertholet","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2018.10.004_bib0175","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/infdis\/jis425","article-title":"Therapeutic immunization against mycobacterium tuberculosis is an effective adjunct to antibiotic treatment","volume":"207","author":"Coler","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2018.10.004_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(18)30077-8","article-title":"Safety and immunogenicity of the novel tuberculosis vaccine ID93\u2008+\u2008GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial","volume":"6","author":"Penn-Nicholson","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.smim.2018.10.004_bib0185","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/bs.apar.2015.04.001","article-title":"Development of malaria transmission-blocking vaccines: from concept to product","volume":"89","author":"Wu","year":"2015","journal-title":"Adv. Parasitol."},{"key":"10.1016\/j.smim.2018.10.004_bib0190","series-title":"The Candidate Blood Stage Malaria Vaccine P27A Induces a Robust Humoral Response in a Fast Track to the Field Phase I Trial in Exposed and Non Exposed Volunteers","author":"Steiner-monard","year":"2018"},{"key":"10.1016\/j.smim.2018.10.004_bib0195","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nbt1015-1015","article-title":"Landmark green light for Mosquirix malaria vaccine","volume":"33","author":"Morrison","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.smim.2018.10.004_bib0200","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120692","article-title":"TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25","volume":"3","author":"Thompson","year":"2018","journal-title":"JCI Insight."},{"key":"10.1016\/j.smim.2018.10.004_bib0205","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1016\/j.vaccine.2013.04.037","article-title":"HIV\/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques","volume":"31","author":"Li","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.10.004_bib0210","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.vaccine.2016.03.016","article-title":"Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen","volume":"34","author":"Baldwin","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.10.004_bib0215","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1016\/j.vaccine.2013.09.069","article-title":"TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses","volume":"31","author":"Fox","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.10.004_bib0220","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-3024.2009.01142.x","article-title":"Adjuvants for malaria vaccines","volume":"31","author":"Coler","year":"2009","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.smim.2018.10.004_bib0225","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1128\/IAI.02980-14","article-title":"Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block plasmodium falciparum infection of mosquitoes","volume":"83","author":"Patra","year":"2015","journal-title":"Infect. Immun."},{"key":"10.1016\/j.smim.2018.10.004_bib0230","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1128\/IAI.05257-11","article-title":"Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic toll-like receptor 4 agonist formulated in an emulsion","volume":"79","author":"Lumsden","year":"2011","journal-title":"Infect. Immun."},{"key":"10.1016\/j.smim.2018.10.004_bib0235","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/COH.0b013e3283632c26","article-title":"Novel directions in HIV-1 vaccines revealed from clinical trials","volume":"8","author":"Excler","year":"2013","journal-title":"Curr. Opin. HIV AIDS."},{"key":"10.1016\/j.smim.2018.10.004_bib0240","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev-med-052912-123749","article-title":"Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection","volume":"66","author":"Kim","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.smim.2018.10.004_bib0245","doi-asserted-by":"crossref","first-page":"E992","DOI":"10.1073\/pnas.1423669112","article-title":"Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection","volume":"112","author":"Fouts","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.smim.2018.10.004_bib0250","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.virol.2014.10.001","article-title":"HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques","volume":"471\u2013473","author":"Thomas","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.smim.2018.10.004_bib0255","first-page":"13","article-title":"Schistosomiasis","volume":"4","author":"McManus","year":"2018","journal-title":"Nat. Rev."},{"key":"10.1016\/j.smim.2018.10.004_bib0260","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.vaccine.2015.10.027","article-title":"Schistosomiasis vaccine candidate Sm14\/GLA-SE: phase 1 safety and immunogenicity clinical trial in healthy, male adults","volume":"34","author":"Santini-Oliveira","year":"2016","journal-title":"Vaccine."},{"key":"10.1016\/j.smim.2018.10.004_bib0265","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/IAI.00748-12","article-title":"Effects of treatment on IgE responses against parasite allergen-like proteins and immunit to reinfection in childhood schistosome and hookworm coinfections","volume":"81","author":"De Moira","year":"2013","journal-title":"Infect. Immun."},{"key":"10.1016\/j.smim.2018.10.004_bib0270","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/ACI.0000000000000212","article-title":"Toll-like receptors as targets for allergen immunotherapy","volume":"15","author":"Aryan","year":"2015","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.smim.2018.10.004_bib0275","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.vaccine.2013.12.057","article-title":"Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons","volume":"32","author":"Karmakar","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.10.004_bib0280","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1093\/infdis\/jiu031","article-title":"Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons","volume":"209","author":"Karmakar","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2018.10.004_bib0285","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.vaccine.2004.09.018","article-title":"Characterization of the immune response to DNA vaccination strategies for schistosomiasis candidate antigen, Sm-p80 in the baboon","volume":"23","author":"Siddiqui","year":"2005","journal-title":"Vaccine."},{"key":"10.1016\/j.smim.2018.10.004_bib0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000313","article-title":"Complexities of assessing the disease burden attributable to leishmaniasis","volume":"2","author":"Bern","year":"2008","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.smim.2018.10.004_bib0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One."},{"key":"10.1016\/j.smim.2018.10.004_bib0300","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-3024.2009.01102.x","article-title":"Genetics and visceral leishmaniasis: of mice and man","volume":"31","author":"Blackwell","year":"2009","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.smim.2018.10.004_bib0305","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/infdis\/jit401","article-title":"CD8 T cell exhaustion in human visceral leishmaniasis","volume":"209","author":"Gautam","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2018.10.004_bib0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003198","article-title":"Leishmania specific CD4 T cells release IFN\u03b3 that limits parasite replication in patients with visceral leishmaniasis","volume":"8","author":"Kumar","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.smim.2018.10.004_bib0315","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1172\/JCI112209","article-title":"Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis","volume":"76","author":"Carvalho","year":"1985","journal-title":"J Clin Invest."},{"key":"10.1016\/j.smim.2018.10.004_bib0320","doi-asserted-by":"crossref","first-page":"e1003053","DOI":"10.1371\/journal.ppat.1003053","article-title":"Determinants for the development of visceral leishmaniasis disease","volume":"9","author":"McCall","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.smim.2018.10.004_bib0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002914","article-title":"Immune regulation during chronic visceral leishmaniasis","volume":"8","author":"Faleiro","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.smim.2018.10.004_bib0330","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.4049\/jimmunol.152.12.5949","article-title":"Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis","volume":"152","author":"Carvalho","year":"1994","journal-title":"J Immunol."},{"key":"10.1016\/j.smim.2018.10.004_bib0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010107","article-title":"Quantification of parasite load in clinical samples of leishmaniasis patients: Il-10 level correlates with parasite load in visceral leishmaniasis","volume":"5","author":"Verma","year":"2010","journal-title":"PLoS One."},{"key":"10.1016\/j.smim.2018.10.004_bib0340","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.it.2007.07.004","article-title":"Interleukin-10 and the pathogenesis of human visceral leishmaniasis","volume":"28","author":"Nyl\u00e9n","year":"2007","journal-title":"Trends Immunol."},{"key":"10.1016\/j.smim.2018.10.004_bib0345","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/0974-777X.62876","article-title":"Immunological perspectives of leishmaniasis","volume":"2","author":"Nyl\u00e9n","year":"2010","journal-title":"J. Glob. Infect. Dis."},{"key":"10.1016\/j.smim.2018.10.004_bib0350","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/0952-7915(93)90033-O","article-title":"T-cell and cytokine responses in leishmaniasis","volume":"5","author":"Reed","year":"1993","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.smim.2018.10.004_bib0355","doi-asserted-by":"crossref","first-page":"A58","DOI":"10.1016\/S0167-5699(05)80017-9","article-title":"Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function","volume":"12","author":"Locksley","year":"1991","journal-title":"Immunol. Today."},{"key":"10.1016\/j.smim.2018.10.004_bib0360","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/0923-2494(91)90008-7","article-title":"Host and parasite factors regulating the development of CD4+ T-cell subsets in experimental cutaneous leishmaniasis","volume":"142","author":"Scott","year":"1991","journal-title":"Res. Immunol."},{"key":"10.1016\/j.smim.2018.10.004_bib0365","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2018.10.004_bib0370","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1038\/cti.2016.63","article-title":"A structure-function approach to optimizing TLR4 ligands for human vaccines","volume":"5","author":"Carter","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.smim.2018.10.004_bib0375","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(06)70412-1","article-title":"The role of BCG in prevention of leprosy: a meta-analysis","volume":"6","author":"Setia","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.smim.2018.10.004_bib0380","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.trstmh.2008.04.015","article-title":"Effectiveness of BCG vaccination among leprosy contacts: a cohort study","volume":"102","author":"D\u00fcppre","year":"2008","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.smim.2018.10.004_bib0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000167","article-title":"BCG revaccination does not protect against leprosy in the Brazilian Amazon: a cluster randomised trial","volume":"2","author":"Cunha","year":"2008","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.smim.2018.10.004_bib0390","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children","volume":"336","author":"Chang","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2018.10.004_bib0395","doi-asserted-by":"crossref","DOI":"10.1086\/344271","article-title":"The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis","volume":"35","author":"Fisman","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.smim.2018.10.004_bib0400","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14760584.2.1.9","article-title":"Immunogenicity of TwinrixTM in older adults: a critical analysis","volume":"2","author":"Stoffel","year":"2003","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.smim.2018.10.004_bib0405","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1080\/00365540110080881","article-title":"A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of engerixTM-B in healthy young adults","volume":"34","author":"Levie","year":"2002","journal-title":"Scand. J. Infect. Dis."},{"key":"10.1016\/j.smim.2018.10.004_bib0410","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1111\/j.1523-1755.2005.00689.x","article-title":"Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients","volume":"68","author":"Tong","year":"2005","journal-title":"Kidney Int."},{"key":"10.1016\/j.smim.2018.10.004_bib0415","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1586\/14760584.6.2.133","article-title":"New hepatitis B vaccine formulated with an improved adjuvant system","volume":"6","author":"Kundi","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.smim.2018.10.004_bib0420","unstructured":"A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02434848."},{"key":"10.1016\/j.smim.2018.10.004_bib0425","first-page":"381","article-title":"Sustained immunogenicity and efficacy of the HPV-16\/18 AS04-adjuvanted vaccine: Up to 8.4 years of follow-up","volume":"8","author":"Roteli-Martins","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.smim.2018.10.004_bib0430","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2018.10.004_bib0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140926","article-title":"Relationship between humoral immune responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 year old girls receiving Cervarix\u00ae or Gardasil\u00ae vaccine","volume":"10","author":"Godi","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.smim.2018.10.004_bib0440","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br. J. Cancer."},{"key":"10.1016\/j.smim.2018.10.004_bib0445","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2159-8290.CD-11-0131","article-title":"Prevention of persistent human papillomavirus infection by an HPV16\/18 vaccine: a community-based randomized clinical trial in guanacaste, Costa Rica","volume":"1","author":"Herrero","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.smim.2018.10.004_bib0450","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.smim.2018.10.004_bib0455","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus\u2010like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV\u2010naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2018.10.004_bib0460","doi-asserted-by":"crossref","first-page":"17585","DOI":"10.1073\/pnas.1207308109","article-title":"Adjuvant solution for pandemic influenza vaccine production","volume":"109","author":"Clegg","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.smim.2018.10.004_bib0465","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV 16\/18 ASO4 - adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4 year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.smim.2018.10.004_bib0470","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Munoz","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.smim.2018.10.004_bib0475","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"T.F.I.S. Group","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2018.10.004_bib0480","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2018.10.004_bib0485","unstructured":"FDA Advisory Committe on Shingrix, (2017). https:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/bloodvaccinesandotherbiologics\/vaccinesandrelatedbiologicalproductsadvisorycommittee\/ucm604344.pdf."},{"key":"10.1016\/j.smim.2018.10.004_bib0490","unstructured":"CDC Considerations for the use of Herpes Zoster Vaccines, (2017). https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2017-10\/zoster-04-dooling.pdf."},{"key":"10.1016\/j.smim.2018.10.004_bib0495","series-title":"New GSK Shingles Vaccine off to Strong Start in Key U.S. Market","author":"Hirschler","year":"2018"},{"key":"10.1016\/j.smim.2018.10.004_bib0500","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/infdis\/171.6.1576","article-title":"Safety, immunogenicity, and efficacy of a recombinantly produced plasmodium falciparum circumsporozoite protein-hepatitis b surface antigen subunit vaccine","volume":"171","author":"Gordon","year":"1995","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.smim.2018.10.004_bib0505","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0140-6736(04)17223-1","article-title":"Efficacy of the RTS,S\/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial","volume":"364","author":"Alonso","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.smim.2018.10.004_bib0510","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","year":"2015","journal-title":"Lancet"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532318300381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532318300381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:13:34Z","timestamp":1760915614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532318300381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":102,"alternative-id":["S1044532318300381"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2018.10.004","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlates of GLA family adjuvants\u2019 activities","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2018.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}